Literature DB >> 16886905

A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis.

John de Kruif1, Alexander B H Bakker, Wilfred E Marissen, R Arjen Kramer, Mark Throsby, Charles E Rupprecht, Jaap Goudsmit.   

Abstract

The currently recommended treatment for individuals exposed to rabies virus is the combined administration of rabies vaccine and rabies immune globulin (RIG). This review sets out the criteria used to guide development of a cocktail of human monoclonal antibodies as a replacement for RIG. Using this process as a model, the general requirements for development of safe and efficacious monoclonal antibody alternatives to currently used polyclonal serum products are discussed.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 16886905     DOI： 10.1146/annurev.med.58.061705.145053

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN： 0066-4219            Impact factor:   13.739


  26 in total

1.  Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus.

Authors:  Chen Li; Feng Zhang; Hong Lin; Zhong-can Wang; Xin-jian Liu; Zhen-qing Feng; Jin Zhu; Xiao-hong Guan
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150

2.  The Generation of the Human mAb RabD4 Specific to the Rabies Virus Glycoprotein and Characterization Thereof.

Authors:  E N Ilina; E V Solopova; T K Aliev; M V Larina; D S Balabashin; N E Varlamov; D A Dolgikh; P G Sveshnikov; M P Kirpichnikov
Journal:  Dokl Biochem Biophys       Date:  2019-06-14       Impact factor: 0.788

3.  Passive protection assay of monoclonal antibodies against dengue virus in suckling mice.

Authors:  Zongtao Chen; Li-Mei Liu; Na Gao; Xiao-Feng Xu; Jun-Lei Zhang; Jia-Li Wang; Jing An
Journal:  Curr Microbiol       Date:  2009-02-03       Impact factor: 2.188

4.  Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent.

Authors:  Séverine Fagète; Ulla Ravn; Franck Gueneau; Giovanni Magistrelli; Marie H Kosco-Vilbois; Nicolas Fischer
Journal:  MAbs       Date:  2009 May-Jun       Impact factor: 5.857

5.  Characterization of a human antibody fragment Fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine.

Authors:  Xinjian Liu; Hong Lin; Qi Tang; Chen Li; Songtao Yang; Zhongcan Wang; Changjun Wang; Qing He; Brian Cao; Zhenqing Feng; Xiaohong Guan; Jin Zhu
Journal:  PLoS One       Date:  2011-05-09       Impact factor: 3.240

Review 6.  Antibodies against viruses: passive and active immunization.

Authors:  Mansun Law; Lars Hangartner
Journal:  Curr Opin Immunol       Date:  2008-07-01       Impact factor: 7.486

7.  Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans.

Authors:  Thomas Müller; Bernhard Dietzschold; Hildegund Ertl; Anthony R Fooks; Conrad Freuling; Christine Fehlner-Gardiner; Jeannette Kliemt; Francois X Meslin; Richard Franka; Charles E Rupprecht; Noël Tordo; Alexander I Wanderler; Marie Paule Kieny
Journal:  PLoS Negl Trop Dis       Date:  2009-11-03

8.  Single domain antibody multimers confer protection against rabies infection.

Authors:  Bhargavi M Boruah; Dawei Liu; Duan Ye; Tie-Jun Gu; Chun-Lai Jiang; Mingsheng Qu; Edward Wright; Wei Wang; Wen He; Changzhen Liu; Bin Gao
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

9.  Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants.

Authors:  Mookkan Prabakaran; Nayana Prabhu; Fang He; Qian Hongliang; Hui-Ting Ho; Jia Qiang; Tao Meng; Michael Goutama; Jimmy Kwang
Journal:  PLoS One       Date:  2009-05-22       Impact factor: 3.240

10.  Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody.

Authors:  Craig J van Dolleweerd; Audrey Y-H Teh; Ashley C Banyard; Leonard Both; Hester C T Lotter-Stark; Tsepo Tsekoa; Baby Phahladira; Wonderful Shumba; Ereck Chakauya; Claude T Sabeta; Clemens Gruber; Anthony R Fooks; Rachel K Chikwamba; Julian K-C Ma
Journal:  J Infect Dis       Date:  2014-02-07       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.